P.O. Box 50030 London, ON N6A 6H8 info@rett.ca (519) 474-6877

DAYBUE – Breaking News

Approves

Acadia Pharmaceuticals Announces

Health Canada Approval of DAYBUE (trofinetide) for the Treatment of Rett Syndrome.

 
DAYBUE is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare neurodevelopmental disorder. We recognize the incredible sacrifices made by individuals with Rett syndrome and their families who participated in the clinical trials. Thanks to their courage, along with the dedication and perseverance of Acadia Pharmaceuticals, we have reached a pivotal milestone for Canadian families. We are grateful to everyone involved in making this treatment a reality today.